𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adeno-associated virus-mediated gene delivery

✍ Scribed by Richard O. Snyder


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
117 KB
Volume
1
Category
Article
ISSN
1099-498X

No coin nor oath required. For personal study only.

✦ Synopsis


Several gene delivery vehicles are being developed for somatic gene therapy and each of these vectors has unique properties which makes them appropriate for different human disease applications. Recombinant adenoassociated viral (rAAV) vectors are proving themselves to be safe and ef®cacious for the long-term expression of proteins and correction of genetic diseases following a single administration. The increasing number of tissues and diseases being targeted with rAAV vectors demonstrates their versatility and has resulted in different approaches for enhancing vector performance. Improving the methods for large-scale manufacturing, and accumulating safety and ef®cacy data in animals and humans are areas of intense research.


📜 SIMILAR VOLUMES


In vivo gene delivery to articular chond
✍ M Ulrich-Vinther; M.R Duch; K Søballe; R.J O’Keefe; E.M Schwarz; F.S Pedersen 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 917 KB

## Abstract __Purposes__. (1) To investigate the efficiency of direct in vivo adeno‐associated virus (AAV) vector‐mediated gene transduction to chondrocytes in relation to normal and injured articular cartilage. (2) To evaluate the effects of ultra‐violet light‐activated gene transduction (LAGT) in

Gene delivery to the vasculature mediate
✍ S. Sen; S. Conroy; S. O. Hynes; J. McMahon; A. O'Doherty; J. S. Bartlett; Y. Akh 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 690 KB

## Abstract ## Background Vascular gene therapy requires safe and efficient gene transfer __in vivo__. Recombinant adeno‐associated virus (AAV) is a promising viral vector but its use in the vasculature has produced conflicting results and serotypes other than AAV2 have not been intensively studie

Intra-articular gene delivery and expres
✍ Jesse D. Kay; Elvire Gouze; Thomas J. Oligino; Jean-Noel Gouze; Rachael S. Watso 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

## Abstract ## Background The adeno‐associated virus (AAV) has many safety features that favor its use in the treatment of arthritic conditions; however, the conventional, single‐stranded vector is inefficient for gene delivery to fibroblastic cells that primarily populate articular tissues. This

Adeno-associated virus-mediated gene tra
✍ Arun Srivastava 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 327 KB

## Abstract Although the remarkable versatility and efficacy of recombinant adeno‐associated virus 2 (AAV2) vectors in transducing a wide variety of cells and tissues in vitro, and in numerous pre‐clinical animal models of human diseases in vivo, have been well established, the published literature

Effect of polyethylenimine on recombinan
✍ Paul Yueh-Jen Hsu; Ya-Wun Yang 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB

Background Recombinant adeno-associated virus (rAAV) is becoming a promising vector for gene therapy for type I diabetes. The objective of this study was to investigate the effect of incorporation of polyethylenimine (PEI) on rAAV-mediated insulin gene therapy in vitro and in vivo. ## Methods Rec

Recombinant adeno-associated virus-media
✍ Hong Ma; Yanxin Liu; Shilian Liu; Hsiang-Fu Kung; Xueying Sun; Dexian Zheng; Rui 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 524 KB

## Abstract To evaluate the tumoricidal activity of tumor necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) on disseminated liver metastatic tumors, we constructed a recombinant adeno‐associated virus (rAAV) expressing the extracellular domain (95–281aa) of human TRAIL (TRAIL~95–281~,